Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Net Income: 2009-2024

Historic Net Income for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$18.6 million.

  • Lineage Cell Therapeutics' Net Income fell 13.96% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.0 million, marking a year-over-year decrease of 59.75%. This contributed to the annual value of -$18.6 million for FY2024, which is 13.49% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Net Income stood at -$18.6 million for FY2024, which was up 13.49% from -$21.5 million recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Net Income high stood at -$18.6 million for FY2024, and its period low was -$43.3 million during FY2021.
  • Over the past 3 years, Lineage Cell Therapeutics' median Net Income value was -$21.5 million (recorded in 2023), while the average stood at -$22.1 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Net Income tumbled by 109.19% in 2021, and later surged by 39.10% in 2022.
  • Lineage Cell Therapeutics' Net Income (Yearly) stood at -$20.7 million in 2020, then slumped by 109.19% to -$43.3 million in 2021, then soared by 39.10% to -$26.4 million in 2022, then grew by 18.50% to -$21.5 million in 2023, then grew by 13.49% to -$18.6 million in 2024.